Global Wealth Management Investment Advisory Inc. Has $1.36 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Global Wealth Management Investment Advisory Inc. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,574 shares of the medical instruments supplier’s stock after buying an additional 452 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Becton, Dickinson and Company were worth $1,359,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Phraction Management LLC raised its position in Becton, Dickinson and Company by 27.9% in the fourth quarter. Phraction Management LLC now owns 32,924 shares of the medical instruments supplier’s stock worth $8,028,000 after purchasing an additional 7,183 shares in the last quarter. Hartford Funds Management Co LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $417,000. Savant Capital LLC increased its position in shares of Becton, Dickinson and Company by 61.6% during the 4th quarter. Savant Capital LLC now owns 7,903 shares of the medical instruments supplier’s stock worth $1,927,000 after purchasing an additional 3,012 shares in the last quarter. Mission Wealth Management LP lifted its holdings in Becton, Dickinson and Company by 23.5% during the 4th quarter. Mission Wealth Management LP now owns 2,360 shares of the medical instruments supplier’s stock valued at $576,000 after purchasing an additional 449 shares during the last quarter. Finally, Van ECK Associates Corp boosted its position in Becton, Dickinson and Company by 3.2% in the fourth quarter. Van ECK Associates Corp now owns 10,832 shares of the medical instruments supplier’s stock valued at $2,641,000 after buying an additional 337 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Raymond James raised their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $280.00.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $0.59 during trading on Wednesday, reaching $234.01. The company had a trading volume of 1,036,535 shares, compared to its average volume of 1,360,445. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The business’s 50 day moving average price is $238.98 and its 200-day moving average price is $240.76. The stock has a market cap of $67.61 billion, a PE ratio of 55.59, a PEG ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. During the same quarter in the previous year, the company posted $2.98 EPS. Becton, Dickinson and Company’s revenue was up 2.6% on a year-over-year basis. Analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 90.05%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.